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ABSTRACT
SCUDO (Signature-based ClUstering for DiagnOstic
purposes) is an online tool for the analysis of gene
expression profiles for diagnostic and classification
purposes. The tool is based on a new method for
the clustering of profiles based on a subject-specific,
as opposed to disease-specific, signature. Our ap-
proach relies on construction of a reference map of
transcriptional signatures, from both healthy and af-
fected subjects, derived from their respective mRNA
or miRNA profiles. A diagnosis for a new individual
can then be performed by determining the position of
the individual’s transcriptional signature on the map.
The diagnostic power of our method has been con-
vincingly demonstrated in an open scientific com-
petition (SBV Improver Diagnostic Signature Chal-
lenge), scoring second place overall and first place
in one of the sub-challenges.
INTRODUCTION
An important task in molecular biology is the accurate
classification of biological specimens on the base of their
gene expression profiles. Methods for accurate and repro-
ducible classification are increasingly required for the po-
tential biomedical applications of expression profiles, such
as disease classification, diagnosis and monitoring. In this
paper we describe SCUDO, a web server implementing
an original signature identification method. Given a set
of expression profiles from control and affected subjects,
SCUDO verifies the existence of a signature (actually, a set
of signatures, as explained below) that can be used to clas-
sify the profiles according to a phenotype of interest, such
as the control/affected status. The method is composed of a
sequence of simple processing steps, none of which is origi-
nal; however their combination results in a robust and novel
model of profile data analysis, that corresponds to a differ-
ent way of exploiting similarities and differences among bi-
ological samples for classification purposes. Specifically, the
originality of the method is that it introduces a new concept
of subject-specific signatures, as opposed to disease-specific
signatures, that also includes the benefits of rank-based clas-
sification, data dimensionality reduction and the power of
network analysis in its design.
Our method was tested against a selection of the best
current approaches in the course of the SBV IMPROVER
Diagnostic Signature Challenge, an open competition de-
signed to assess and verify computational approaches for
classifying clinical samples based on gene expression (1).
In an effort to increase robustness of the outcome with re-
spect to chance and disease specificity, the SBV Challenge
required a diagnosis for all of four diseases, namely Pso-
riasis, Multiple Sclerosis (MS), Chronic Obstructive Pul-
monary Disease (COPD) and Lung Cancer. For each dis-
ease, the organizers (a team of researchers from IBM Re-
search and Philip Morris International) suggested a list of
publicly available mRNA expression datasets to use as pos-
sible training sets and then solicited a healthy/affected diag-
nosis for a previously unpublished set of profiles (test set).
The submitted predictions were scored by the organizers ac-
cording to a combination of three previously selected met-
rics: the Area Under the Precision-Recall Curve (AUPR),
the Belief Confusion Metric (BCM) and the Correct Class
Enrichment Metric (CCEM).
The method implemented in SCUDO ranked second
overall, and first in the MS sub-challenge, out of 54 sub-
missions. Interestingly, the MS Diagnostic appeared to be
the most difficult of the four, according to the plots of the
distribution of random versus observed scores prepared by
the organizers. The overall first placement was achieved by
the winning team through a skillful application of Linear
Discriminant Analysis (LDA); the third place was obtained
by a team that applied Lasso Regression (2). (See (3) and
(4), respectively, for the details of the winning methods and
of the scoring algorithm and score distribution plots.)
Themethod onwhich SCUDO is based represents a com-
pletely new way of addressing the expression profile classi-
fication problem. Contrary to current practices, instead of
evaluating a set of profiles by means of a common yard-
stick (a single list of highly discriminating mRNA/miRNA
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species), our method first seeks to summarize the charac-
teristics of each profile by means of a rank-based signature
and then it performs a systematic, all-to-all signature com-
parison. The comparison consists in the measurement of
a distance that quantifies the degree of similarity between
any two signatures using a simplified version of the En-
richment Score (ES) (5). The result of the comparison is
a distance matrix, which is then visualized in the form of
a map of individual signatures. In such a map, the sponta-
neous emergence of groups (i.e. clusters of closely connected
nodes) of transcriptionally similar subjects is typically ob-
served. In a diagnostic application, the observed groups seg-
regate the subjects according to their control/affected phe-
notype. A diagnostic classification for an unseen individual
can subsequently be performed by determining the position
of the individual’s transcriptional signature relative to the
control/affected groups. Further details of the method are
described in (6).
The signature map is the output of SCUDO. The map
is in the form of a graph where the nodes correspond to
signatures/subjects and the length of a connecting edge en-
codes the level of similarity between the connected nodes
(short edge = high similarity; no edge = negligible similar-
ity). SCUDOaccepts two separate datasets as input, respec-
tively a testing and a training dataset, but it can also be used
with a single (training) dataset. If a testing set is specified,
SCUDO runs the same rank-based classification algorithm
on it, but it skips the feature selection step, using instead the
list of features (genes or miRNAs) already selected for the
training dataset. The optimization of the signature length is
left to the user and is performed by trial and error; in prac-
tice the user needs to try and select the n1 and n2 values that
provide the clearest separation between the affected and the
control subjects (n1= number of up-regulated genes to con-
sider, n2 = number of down-regulated genes, n1 + n2 being
the total signature length). Crucially, we have shown that
our method is robust to variations of its input parameter
values, therefore the selection process is not critical and sat-
isfactory values can be found with only a few iterations (6).
The expected result is the emergence of a partitioning of the
set of samples in separate, clearly visible groups on the basis
of signature similarity. While for the training set the sample
classification is known in advance and thus the correctness
of the partitioning is immediately verified by the appear-
ance of homogeneously colored groups, for the test set in
general the sample classification is the desired final output
and needs to be deduced from the graph. The classification
problem for the test set is then reduced to the simpler task
of identifying the control/affected phenotype associated to
each of the emerging groups in the test graph, in what we
call the labeling step. This relatively simple labeling step can
be carried out by means of empirical methods that rely on
some form of previous knowledge. One form of previous
knowledge consists of a small number of samples for which
the classification is known; by adding these samples to the
test set, one can deduce the labeling of the groups based
on the membership of the known samples. Another form
of previous knowledge is represented by a list of literature-
derived disease genes; by computing the average expression
values of these genes across all the members of a group, one
can deduce the labeling of the groups by comparing aver-
ages and taking a majority vote. We used both these meth-
ods for the labeling of samples in the SBV Improver com-
petition.
Our rank-based signature method is quite general and
we have tested it successfully with a large assortment
of data types: mRNA and miRNA profiles for various
diseases/treatments/experiments, obtained from biopsies,
blood and urine and even some non-biological multidi-
mensional datasets (i.e. engineering data). With SCUDO
we are making available an online implementation of our
new method to encourage experimentation and discovery
of novel applications.
THE SCUDO INTERFACE: THE INPUT
SCUDO accepts a testing and a training dataset as input
(Figure 1), but it can also be used with a single (training)
dataset, in case the user is not interested in the testing step.
If a testing set is specified, SCUDO produces a map of the
profiles using the same list of features (genes or miRNAs)
that were used in producing the training profiles map. In a
sense, the testing set is used to validate the quality of the fea-
ture list, obtained examining the training set, as a starting
point in producing discriminating signatures for a different
set of profiles.
A microarray expression dataset to be analyzed needs
to have been previously normalized; the choice of the al-
gorithm is not critical (i.e. either MAS5 or RMA can be
used for Affymetrix platforms; either calibrated or uncali-
brated data can be used for RT-PCR profiles), the data does
not need to be log transformed. The data must be in a tab-
separated text format, with one gene or probeset per row,
and one sample (i.e. a patient profile) per column; the test-
ing and training datasets must have the same number of
rows and the same gene/probeset on corresponding rows.
The first column of the file is reserved for a gene/probeset
identifier while the first row of the file is used for sample
identifiers. Both set of identifiers must be unique charac-
ter strings without spaces; the leftmost field of the first row,
corresponding to the probeset ID column, needs to be filled
with a placeholder character string. Assuming that the user
is using both a training and a testing dataset, the typical
analysis workflow is as follows: upload the two data files,
specify the algorithm parameters, launch the analysis, ex-
amine the two resulting maps (one for the training profiles,
the other for the testing profiles). After inspecting the maps,
the user can repeat the same process with different param-
eter values, for example with a different signature size. The
input parameters to be specified on the start page are:
(i) column ranges corresponding to the two classes of pro-
files (i.e. control, affected) in the training dataset
(ii) n1= number of genes from top ranked genes to include
in signature
(iii) n2 = number of genes from bottom ranked genes to
include in signature
(iv) pval = P-value to be used for the initial feature selec-
tion
(v) N= percentage of all of the signature-to-signature dis-
tances that will be used for drawing themap of subjects.
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Figure 1. Snapshot of the SCUDO start page. The input data fields for the training set are on the left, the ones for the testing set on the right.
The user has the option to use the same file for the
training and testing dataset, presumably selecting different
ranges of columns as the training and the testing sets. The
column ranges specified by the user for the testing set are
also used to assign different colors to the two groups of sam-
ples. Only the specified columns for both sets are used for
the analysis.
In the current version of SCUDO, the optimization of in-
put parameters such as the signature length and theP-value
of the feature selection step is left to the user and is per-
formed by trial and error. In a typical session, the user needs
to try and select the n1 and n2 values that provide the clear-
est separation between the affected and the control subjects
in the output maps, starting with the suggested value of
P-value (0.01 for mRNA, 0.1 for miRNA profiles). Based
on our experience with a large number of representative
datasets, good starting values for n1 and n2 are 250/250 for
mRNA, 25/25 for miRNA and these values can be repeat-
edly doubled or halved until good separation is achieved;
if unsuccessful, a more stringent P-value can be tried. The
P-value is not critical because it does not represent a thresh-
old for inclusion of crucial features in a signature; rather, the
main purpose of the initial feature selection step is to pre-
vent pollution of signature composition by non-informative
features (i.e. to remove the probesets/genes that are stuck
high or low). The value of N is finally adjusted to improve
clarity of the map by either reducing the clutter (smaller N)
or increasing the number of connecting edges (larger N) as
needed.
THE SCUDO INTERFACE: THE OUTPUT
The output of the tool is a map for each of the input dataset
(see Figure 2). The nodes in the map correspond to sub-
jects and the length of a connecting edge encodes the level of
similarity between the connected nodes (short edge = high
similarity; no edge = negligible similarity). The map is in
the form of a network drawn using Cytoscape Web, which
allows manipulation and setting of display attributes. The
desired outcome of the analysis is a map of the testing set
in which the profiles are clearly divided in two groups com-
posed of nodes of the same color; such result would give
high confidence in the fact that using the selected feature
list the user will be able to satisfactorily classify a new set
of profiles using signatures composed of the n1 + n2 most
differentially expressed genes of each profile.
Once the user is satisfied with the result, he/she can
download the maps as graphical files, or as network files
(edge list) ready to be imported in Cytoscape (7) or simi-
lar tools. A Cytoscape plugin such as clusterMaker (8) can
be useful in identifying clusters in those maps in which the
boundaries between groups are not immediately apparent
(as in the right map of Figure 2); see reference (6) for an ex-
ample of use of such plugin. The user can also download a
file containing the subject specific signatures (one column
per subject) plus two ‘consensus signatures’ (one for each
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Figure 2. Snapshot of the SCUDO result page; the map for the training data is on the left, the one for the testing data on the right.
of the two groups indicated by the user). The consensus sig-
nature for each group is computed as follows: the rank of
each gene in a profile is computed separately for each sub-
ject by sorting expression values from the most expressed
to the least expressed, then the columns of gene ranks cor-
responding only to the subjects included in the group are
summed row-wise and the resulting rank sums are sorted
to provide a new set of ‘consensus ranks’; the signature for
the group is then composed by the first n1 and the last n2
gene IDs ordered according to the new consensus rank list.
The consensus signature is reminiscent of a disease gene list
although derived using our unconventional approach and
can be used to study the underlying molecular mechanism
of a disease (for an instance of such an application see (9)).
SAMPLE DATA
A sample set of expression profiles and corresponding sug-
gested parameter values are available in the initial page.
The sample datasets provide an interesting example of the
versatility of SCUDO. The two datasets comprise pro-
files of circulating miRNA in patient with early breast
cancer and matching controls published by two differ-
ent research groups (GEO accession numbers GSE22981
and GSE41526, including 40 and 70 profiles respectively).
GSE41256was used as the training set andGSE22981 as the
testing set, because the larger size of the former improves the
performance of the feature selection step. The two datasets
were used as downloaded from GEO (GSE Series Matrix
format) except for the required changes in the formatting;
also, in the first set we had to remove six rows correspond-
ing to miRNA species that were missing from the other set
(both set use the same platform, Illumina Human v2 Mi-
croRNA Expression Beadchip). The recommended signa-
tures sizes are 20/20 for both sets; the recommended P-
value of 0.001, empirically found to work best, is unchar-
acteristically small for SCUDO, probably reflecting the ex-
istence of high noise levels or confounding signals in the two
datasets.
In the two resulting maps (Figure 2) it can be observed
that (i) in the training set map, SCUDO is able to group
together control and affected patients with good accuracy
and (ii) in the testing set, SCUDO is able to separate control
and affected subjects reasonably well as long as the analysis
is restricted to the subset of Caucasian American individu-
als. These results are of particular interest in view of the fact
that the authors of the first set were not able to identify a re-
producible diagnostic signature (10) and that the authors of
the second set reported differences in terms of differentially
expressed circulating miRNAs between Caucasian Ameri-
can and African American subjects (11).
DISCUSSION
SCUDO implements a new expression profile classification
based on the degree of similarity between profile-specific
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signatures. As a consequence of being rank-based, SCUDO
is quite robust to differences in lab protocols, data process-
ing and batch effects, because it relies only on the relative or-
dering of the gene expression values within each profile, and
not on the values themselves (for more details on this point
see (6)). This robustness can be appreciated in the analysis
of the provided sample data files, which are from the same
Affymetrix platformbut have been produced by different re-
search groups and have undergone different normalizations.
Additionally, we have shown that our method is robust to
wide variations of its parameter values therefore the choice
of the values is not overly critical. Our rank-based signature
method is quite general and we have tested it successfully
with a large assortment of data types: mRNA and miRNA
profiles for various diseases/treatments/experiments, ob-
tained from biopsies, blood and urine, and even some non-
biological multidimensional datasets (i.e. engineering data).
Using publicly available data, we have obtained promising
results on the stratification of patients with respect to treat-
ment response (12) and early diagnosis of cancer based on
blood miRNA (13); we have preliminary results for sample
classification in toxicity studies. The reasons for this gen-
erality are that being completely data driven, our method
is agnostic about the details of the mechanisms producing
the transcriptional response. By making available an on-
line implementation of our new method we want to encour-
age experimentation with new data types and discovery of
novel applications. SCUDO has been used as part of a class
project by the students of a graduate course held at the Uni-
versity of Trento during the Spring 2014 semester, whose
feedback we gratefully acknowledge.
AVAILABILITY
http://www.cosbi.eu/scudo––this website is free and open to
all users.
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